Navigation Links
NicOx Opens U.S. Headquarters in New Jersey

SOPHIA ANTIPOLIS, France, Oct. 15 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today announced the opening of its United States headquarters in Warren, New Jersey, where the Company will base its Commercial Affairs and U.S. Clinical Operations departments. Mr. Sanjiv Sharma, who was appointed last April as Vice President of Commercial Affairs (see press release April 30, 2007), will head the U.S. office (see NOTE). In addition to commercial activities, U.S. Clinical Operations will be based in this office, led by Joan Sutphen, who joined NicOx in February 2007 as Director of U.S. Clinical Operations.

"As NicOx transitions from a pure research and development organization to a fully integrated commercial company, we recognized the need to open NicOx' U.S. headquarters. As we move closer to our anticipated New Drug Application filing for naproxcinod, we will need to build our sales and marketing infrastructure," stated Damian Marron, Vice President of Corporate Development at NicOx. "Over the past few months, Sanjiv has built an excellent U.S.-based team, which has begun to develop commercial strategies for our product portfolio. In addition, Sanjiv's team will provide indispensable support to our management team, particularly relating to new in-licensing and acquisitions opportunities."

NicOx has made additional appointments to the Commercial Affairs team, all of whom have considerable marketing, market research, and business analysis experience. The NicOx' U.S. clinical team will establish a permanent clinical presence in the U.S. where the majority of NicOx' clinical trials are planned and conducted and will help to implement NicOx' U.S. clinical strategy and provide strong support and management of the Clinical Research Organizations (CRO) working for the Company. The 6,000 square feet facility will accommodate additional hires in the coming months, as the Company prepares for the filing of a New Drug Application (NDA) for naproxcinod, NicOx' first in class COX- inhibiting Nitric Oxide Donator (CINOD) for the treatment of the signs and symptoms of osteoarthritis.

Sanjiv Sharma, Vice President Commercial Affairs at NicOx, said, "We selected Warren because many leading global pharmaceutical firms, biotech companies, universities, and hospitals are located in New Jersey, making this a highly attractive location as we build the skills and infrastructure we need in the U.S. Furthermore, we are in close proximity to the global headquarters of Pfizer Inc and Merck & Co., Inc., our collaborators in ophthalmology and hypertension, as well as the contract research organizations which are assisting with naproxcinod's pivotal studies."

Naproxcinod, NicOx' lead investigational product, is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Results from the first pivotal phase 3 study (the 301 study), announced last October (see press release of October 27, 2006), showed naproxcinod had superior efficacy compared to placebo and patients experienced a sustained reduction in blood pressure compared to baseline and the existing anti- inflammatory agent, naproxen. The two remaining pivotal phase 3 studies for naproxcinod (the 302 and 303 studies) currently are ongoing. NicOx is expected to report results in mid-2008 and anticipates filing a NDA for naproxcinod in the U.S. during the first quarter of 2009.


NicOx Inc: 15 Independence Blvd, Warren Township, New Jersey, U.S.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck & Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may differ materially from those indicated in the forward-looking statements because of different risks factors described in the company's document de reference.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NanoRite Innovation Center opens with small science, big promise
2. TomoTherapy opens technical training center
3. Japanese telecom opens liason office at UW-Platteville
4. Test center for RFID capabilities opens next week
5. Eau Claire business-plan contest opens
6. GE Healthcare opens facility meant for 2,000 employees
7. Space Place opens new astronomy center
8. Research on fruit flies opens up possibilities for human treatments
9. Paper technology transfer center opens in Green Bay
10. Nanotech exhibit opens at UW-Madison
11. Doyles Japan trip opens doors and minds for Wisconsin
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
Breaking Biology Technology:
(Date:11/10/2015)... 2015 About signature verification ... to identify and verify the identity of an ... the secure and accurate method of authentication and ... individual because each individual,s signature is highly unique. ... dynamic signature of an individual is compared and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):